Literature DB >> 6213845

Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells.

W L Washtien.   

Abstract

Thymidylate synthetase levels in five human gastrointestinal tumor cell lines (two colon, two colorectal, one stomach) were determined. Titration of the enzyme in cell cytosol using the active-site titrant, 5-fluoro-2'-deoxyuridine-5'-monophosphate, demonstrated a 20-fold variation in the level of this enzyme among the tumor lines. Titrations performed in the presence or absence of added methylenetetrahydrofolate gave the same values for enzyme content. The cytotoxicity of 5-fluorodeoxyuridine to these cell lines (expressed as EC50 values) varied from 0.44 nM for SW 403 cells to 16 nM for HuTu 80 cells, and in all cases was reversed by the addition of thymidine. The concentration of 5-fluorodeoxyuridine required for cytotoxicity correlated directly (r = 0.98) with the level of thymidylate synthetase in the particular cell line. An inverse correlation (r = -0.95) was observed between the concentration of methotrexate producing cytotoxicity in these cell lines and their thymidylate synthetase levels. The cells were found to contain similar levels of dihydrofolate reductase and to possess normal transport capability for methotrexate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213845

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations.

Authors:  Heike Glauner; Ivo R Ruttekolk; Kerrin Hansen; Ben Steemers; Yi-Da Chung; Frank Becker; Stefan Hannus; Roland Brock
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.

Authors:  G A Curt; J Jolivet; D N Carney; B D Bailey; J C Drake; N J Clendeninn; B A Chabner
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

4.  Enhanced therapeutic effect of methotrexate in experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide.

Authors:  A C Kroes; J Lindemans; M Schoester; J Abels
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Impairment of methotrexate (MTX)-polyglutamate formation of MTX-resistant K562 cell lines.

Authors:  S Koizumi
Journal:  Jpn J Cancer Res       Date:  1988-11

Review 6.  Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.

Authors:  Manfred Volm; Thomas Efferth
Journal:  Front Oncol       Date:  2015-12-17       Impact factor: 6.244

7.  Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors.

Authors:  H Kobayashi; Y Takemura; H Miyachi; L Skelton; A L Jackman
Journal:  Jpn J Cancer Res       Date:  1995-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.